Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 15/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16083176 | 0.88 | HDAC1 (0.55) | HDAC1HDAC2HDAC3ADORA2A | |
| SCHEMBL16083160 | 0.83 | HDAC2 (0.56) | HDAC1HDAC2HDAC3KDM1A | |
| SCHEMBL16083087 | 0.83 | HDAC2 (0.55) | HDAC1HDAC2HDAC3ADORA2A | |
| SCHEMBL8420480 | 0.82 | HDAC1 (0.56) | HDAC1HDAC2HDAC3ADORA2A | |
| SCHEMBL3555346 | 0.82 | HDAC1 (0.55) | HDAC1HDAC2ADORA2A | |
| SCHEMBL16056352 | 0.82 | HDAC2 (0.56) | HDAC1HDAC2HDAC3ADORA2A | |
| SCHEMBL21413564 | 0.82 | HDAC2 (0.54) | HDAC1HDAC2HDAC3ADORA2A | |
| SCHEMBL16083165 | 0.82 | HDAC2 (0.66) | HDAC1HDAC2HDAC3METKDM1A | |
| SCHEMBL3554525 | 0.80 | HDAC2 (0.58) | HDAC1HDAC2HDAC3ADORA2A | |
| SCHEMBL16083082 | 0.80 | HDAC2 (0.77) | HDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428028-B2 | HDAC inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10029988-B2 | HDAC inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10029988-B2 | HDAC inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2018-07-24 | — | — | US | disclosed |
| EP-2970139-B1 | HDAC INHIBITORS | BIOMARIN PHARM INC (US) | 2018-05-30 | — | — | EP | disclosed |
| US-20160031823-A1 | HDAC INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160031823-A1 | HDAC INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2016-02-04 | — | — | US | disclosed |
| WO-2014143666-A1 | HDAC INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10029988-B2 | HDAC inhibitors | HDAC1, HDAC2, HDAC11 | HDAC1 1/4885HDAC2 2/4885HDAC3 4/4885 |
| US-10428028-B2 | HDAC inhibitors | HDAC1, HDAC2, HDAC11 | HDAC1 1/4885HDAC2 2/4885HDAC3 4/4885 |
| US-20160031823-A1 | HDAC INHIBITORS | HDAC1, HDAC2, HDAC11 | HDAC1 1/4885HDAC2 2/4885HDAC3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.